BioSpace News Archive

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced financial results for its fiscal year 2023 first quarter that ended June 30, 2022.

eRAD, a subsidiary of RadNet, Inc., announced that Open System Imaging, based in Palm Desert, Calif., has deployed eRAD’s Radiology Information System, Patient Portal and RADAR, its secure clinical communications platform.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 353 owned and operated outpatient imaging centers, reported financial results for its second quarter of 2022.

BeiGene, a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival versus sorafenib as a first-line treatment in adult patients with unresectable hepatocellular carcinoma.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an amendment to its agreement with the European Commission to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the Company’s Omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrade to its full-featured SRT-100 Vision™ system with new state-of-the-art solid state High-Frequency Ultrasound.

Azenta, Inc. reported financial results for the third quarter ended June 30, 2022.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported second quarter financial results for the period ended June 30, 2022, and provided a business update.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2022.